600518.SS Stock Analysis
60
Uncovered
Kangmei Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
3.584
Dividend yield
0.67 %
Shares outstanding
13 828.93 B
Website
http://www.kangmei.com.cn/Kangmei Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical, health care and health food products. The company is headquartered in Shenzhen, Guangdong and currently employs 6,410 full-time employees. The company went IPO on 2001-03-19. The firm's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera flower, among others. The firm is also engaged in the trading of Chinese herbal medicines, medical equipment and healthcare products related businesses. The company also engages in the provision of real estate leasing and distribution services, among others. The firm mainly conducts its businesses within domestic markets.